Bridgebio Oncology Therapeutics Inc — 10-K exhibit

AMENDMENT NO. 7

TO TRANSITION SERVICES AGREEMENT

This Amendment No. 7 (“Amendment No. 7”) to the Agreement (as defined below) is made effective as of October 1, 2025 (the “Effective Date”) by and among BridgeBio Services Inc., a Delaware corporation (“BBIO”), TheRas, Inc., a Delaware corporation (“BBOT”), BridgeBio Pharma LLC (“BBP LLC”), and BridgeBio Oncology Therapeutics, Inc. (“PubCo”). BBIO, BBOT, BBP LLC and PubCo may be referred to herein by name or individually, as a “Party” and collectively, as the “Parties.” Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Agreement (as defined below) to the extent defined therein.

WHEREAS, BBIO and BBOT entered into that certain Transition Services Agreement, dated April 30, 2024, as amended (the “Agreement”);

WHEREAS, the Agreement was subsequently amended to add BBP LLC and PubCo as Parties to the Agreement; and

WHEREAS, the Parties now wish to further amend the Agreement to update the Service Schedule on Exhibit A thereto.

NOW, THEREFORE, in consideration of the covenants, conditions and undertakings hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

[Signature Page Follows]

IN WITNESS WHEREOF, each Party hereto has executed this Amendment No. 7 as of the date first above written.

EXHIBIT A

SERVICE SCHEDULE

Services from October 1, 2025 through December 31, 2025

[***]

Services from January 1, 2026 through March 31, 2026

[***]